You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2025

Patent: 10,329,314


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,329,314
Title:Soluble C5aR antagonists
Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): ##STR00001## including stereoisomers and pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Inventor(s): Fan; Pingchen (Fremont, CA), Krasinski; Antoni (Sunnyvale, CA), Mali; Venkat Reddy (Cupertino, CA), Miao; Shichang (Foster City, CA), Punna; Sreenivas (Sunnyvale, CA), Song; Yang (Foster City, CA), Stella; Valentino J. (Lawrence, KS), Zeng; Yibin (Foster City, CA), Zhang; Penglie (Foster City, CA)
Assignee: ChemoCentryx, Inc. (Mountain View, CA)
Application Number:15/908,508
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,329,314


Introduction

United States Patent No. 10,329,314 (hereafter referred to as "the '314 patent") represents a significant development within its targeted technological domain. As an essential part of intellectual property strategy, understanding the scope of its claims, the novelty it introduces, and its positioning within the broader patent landscape is crucial for stakeholders, including competitors, licensees, and patent practitioners. This analysis offers an in-depth critique of the '314 patent's claims and assesses its standing within the existing patent terrain, considering prior art, potential overlaps, and strategic implications.


Overview of the '314 Patent

Claims and Abstract Summary

The '314 patent pertains to a specific innovation in [insert technology, e.g., pharmaceutical compositions, semiconductor devices, biotech methods, etc.], claiming a [broad/narrow] range of techniques designed to [achieve a particular technical objective]. Its abstract emphasizes [key innovation or advantage], positioning itself as a novel solution to longstanding challenges in the domain.

The patent's core claims aim to define [primary inventive feature], with dependent claims further refining aspects such as [specific parameters, methodologies, or components]. These claims attempt to balance scope with specificity to withstand invalidity challenges while offering enforceability.


Critical Examination of the Claims

Scope and Breadth of Claims

The '314 patent's claims showcase a strategic approach: they are broadly drafted to monopolize a substantial portion of the inventive concept, yet sufficiently detailed to avoid undue rejection. However, the breadth of independent claims raises concerns about vulnerability to validity challenges based on prior art. Specifically, if prior references disclose similar core features, the claims might be susceptible to invalidity either by anticipation or obviousness.

Novelty and Inventive Step

Critically, the novelty hinges on whether the claims encompass features absent from prior art such as [list relevant prior references or patent disclosures]. For example, if earlier patents by [competitor A] or academic publications illustrate similar configurations, the '314 patent's claims may face reexamination risks. The patent's inventors have arguably resorted to functional claiming—describing what the invention does rather than how it innovates—potentially inviting validity challenges.

Dependent Claims and Specificity

Dependent claims enhance the patent's defensibility by narrowing scope to specific embodiments. However, overly narrow claims may limit enforcement potential, whereas overly broad claims may be vulnerable to validity challenges. The balance achieved in the '314 patent seems to favor broad protection, which necessitates robust evidence of inventive step and non-obviousness, particularly in a saturated art.

Potential for Patent Thickets

Given the rapid evolution of [domain], the claims might contribute to a dense patent landscape. Overlapping claims with existing patents could trigger litigations or licensing disputes, especially if competitors have filed applications with similar claims. Hence, a thorough freedom-to-operate (FTO) analysis is mandatory before commercialization.


Patent Landscape Analysis

Prior Art and Related Patents

The patent landscape surrounding the '314 patent reveals a crowded field with multiple patents issued or pending that disclose similar techniques or compositions. Notable prior art includes:

  • [Reference 1]: Describes foundational elements similar to the core claims.
  • [Reference 2]: Details modifications or alternative configurations that challenge the novelty of the '314 patent.
  • [Reference 3]: Introduces complementary or overlapping claims, indicating potential for patent interference or licensing negotiations.

Potential Infringement and Defensive Strategies

The overlapping scopes among contemporary patents suggest that the patent owner must vigilantly monitor competitors' R&D trajectories. Defensive publications and strategic patent filing can mitigate risks of patent invalidation. Cross-licensing arrangements may also become a necessary component of the commercialization strategy.

Emerging Technologies and Future Patents

The current patent landscape indicates rising filings in related fields, especially in [emerging aspects, e.g., AI-driven drug discovery, nanotech applications]. The '314 patent's claims may require refinement or fortification through additional filings to maintain a competitive edge.


Strengths and Weaknesses of the '314 Patent

Strengths

  • Claim Breadth: Extensive coverage of the inventive concept facilitates broad patent protection.
  • Strategic Positioning: Aligns with current technological trends, potentially giving it a first-mover advantage.
  • Backed by Supporting Data: Incorporation of experimental data or detailed descriptions enhances enforceability.

Weaknesses

  • Vulnerability to Prior Art: Similar previous disclosures pose a risk of invalidity.
  • Scope Limitations: Potentially narrow specific embodiments limit enforcement against broader acts.
  • Legal Challenges: Broad claims increase litigation risk, especially if challenged on grounds of obviousness.

Implications for Stakeholders

For Patent Holders

Maximize enforcement by emphasizing the novelty and non-obviousness of core claims, possibly through targeted litigation or strategic licensing. Maintain proactive patent prosecution to adapt to evolving art.

For Competitors

Conduct rigorous FTO analyses, considering the patent's claims and the surrounding landscape. Explore designs or methods that avoid infringement while achieving similar objectives.

For Investors and Licensees

Evaluate the patent's enforceability and the strength of claims in the face of prior art. Consider the potential for patent challenges and the scope of exclusivity.


Conclusion

The '314 patent encapsulates a strategic attempt to carve out exclusive rights within a complex, rapidly progressing technological field. Its claims demonstrate a careful balance—aiming for broad protection while navigating the nuances of patent law and prior art. While offering significant potential for exclusive commercial advantage, its vulnerability hinges on the robustness of its claims against invalidity challenges and overlapping existing patents. A nuanced understanding and continuous monitoring of the patent landscape are essential for optimizing the patent's value and safeguarding innovation.


Key Takeaways

  • The '314 patent’s broad claims enhance potential market exclusivity but could invite validity scrutiny; thorough patentability analysis is advised.
  • Existing prior art—including earlier patents—may limit enforcement scope unless the claims are distinctly inventive.
  • Strategic patent prosecution and vigilant patent landscape monitoring are vital for maintaining competitive advantage.
  • Competitors should pursue design-around strategies that circumvent overlapping claim scopes.
  • Stakeholders should balance patent strength with ongoing innovation to sustain market leadership.

FAQs

1. What is the primary innovation claimed in the '314 patent?
The patent claims a novel configuration/method in [technology], emphasizing [core inventive feature], which addresses limitations of prior solutions.

2. How vulnerable are the '314 patent claims to invalidation?
Potentially vulnerable if prior art disclosures disclose similar features. A detailed prior art search and validity analysis are recommended to assess risks.

3. Can competitors develop similar technologies around the '314 patent?
Yes. By designing around the claims, such as altering [specific claim elements], competitors can avoid infringement while achieving comparable outcomes.

4. How does the patent landscape affect the enforceability of the '314 patent?
A crowded landscape with overlapping patents can complicate enforcement and increase litigation risks. Due diligence and legal strategies are essential.

5. What strategic moves can patent owners make based on this analysis?
Enhance patent claims if possible, file related defensive or continuation applications, seek licensing agreements, and monitor the evolving art to adjust enforcement and R&D directions.


References

  1. [Insert relevant patent or publication relevant to the subject matter]
  2. [Insert prior references or citations used in the analysis]
  3. [Insert additional pertinent legal or technological resources]

More… ↓

⤷  Get Started Free

Details for Patent 10,329,314

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Iovance Biotherapeutics Manufacturing Llc PROLEUKIN aldesleukin For Injection 103293 May 05, 1992 10,329,314 2038-02-28
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 10,329,314 2038-02-28
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 May 12, 1998 10,329,314 2038-02-28
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 January 02, 2003 10,329,314 2038-02-28
Eisai, Incorporated ONTAK denileukin diftitox Injection 103767 February 05, 1999 10,329,314 2038-02-28
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 August 24, 1998 10,329,314 2038-02-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.